- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Trial primary completion date, Monotherapy: An Extension of Protocol PRO 140_CD01 TS Study (clinicaltrials.gov) - Nov 18, 2016
P2, N=28, Active, not recruiting,
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Enrollment closed, Monotherapy: An Extension of Protocol PRO 140_CD01 TS Study (clinicaltrials.gov) - Oct 7, 2016
P2, N=28, Active, not recruiting,
Initiation date: Jul 2016 --> Oct 2016 Recruiting --> Active, not recruiting
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Enrollment closed, Phase classification, Monotherapy: Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection (clinicaltrials.gov) - Oct 7, 2016
P2b, N=43, Active, not recruiting,
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Phase classification: P2 --> P2b
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Enrollment open, Enrollment change, Combination therapy: Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 (clinicaltrials.gov) - Oct 7, 2016
P2/3, N=30, Recruiting,
Recruiting --> Active, not recruiting | Phase classification: P2 --> P2b Active, not recruiting --> Recruiting | N=300 --> 30
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Enrollment closed, Combination therapy: Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 (clinicaltrials.gov) - Jul 29, 2016
P2/3, N=300, Active, not recruiting,
Active, not recruiting --> Recruiting | N=300 --> 30 Recruiting --> Active, not recruiting
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Enrollment open, Monotherapy: An Extension of Protocol PRO 140_CD01 TS Study (clinicaltrials.gov) - Feb 22, 2016
P2, N=28, Recruiting,
Phase classification: P2 --> P2a Active, not recruiting --> Recruiting
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Trial primary completion date, Monotherapy: An Extension of Protocol PRO 140_CD01 TS Study (clinicaltrials.gov) - Feb 12, 2016
P2, N=28, Active, not recruiting,
Active, not recruiting --> Recruiting Trial primary completion date: Jun 2018 --> Jun 2017
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Enrollment open, Trial primary completion date, Combination therapy: Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 (clinicaltrials.gov) - Feb 12, 2016
P2/3, N=300, Recruiting,
Trial primary completion date: Jun 2018 --> Jun 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Aug 2017
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Enrollment closed, Trial primary completion date, Monotherapy: Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection (clinicaltrials.gov) - Feb 12, 2016
P2, N=40, Active, not recruiting,
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Aug 2017 Completed --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jul 2016
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Trial primary completion date, Monotherapy: An Extension of Protocol PRO 140_CD01 TS Study (clinicaltrials.gov) - Nov 19, 2015
P2, N=28, Active, not recruiting,
No longer recruiting --> Completed Trial primary completion date: Jun 2015 --> Jun 2018
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Enrollment open, Trial primary completion date, Adherence: A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence (clinicaltrials.gov) - Nov 19, 2015
P2, N=79, Recruiting,
Trial primary completion date: Jun 2015 --> Jun 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2015 --> Jan 2017
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
New P2/3 trial, Combination therapy: Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 (clinicaltrials.gov) - Jun 26, 2015
P2/3, N=300, Not yet recruiting,
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Enrollment change, Trial withdrawal, Trial primary completion date: PRO 140 for Human Immunodeficiency Virus Infection (clinicaltrials.gov) - Mar 5, 2015
P2, N=0, Withdrawn,
Active, not recruiting --> Completed N=40 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Feb 2015
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Trial initiation date, Adherence: A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence (clinicaltrials.gov) - Jul 24, 2013
P2, N=79, Not yet recruiting,
Recruiting --> Active, not recruiting Initiation date: Dec 2010 --> Dec 2013
|
